International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Summary This International Myeloma Working Group consensus updates the disease
definition of multiple myeloma to include validated biomarkers in addition to existing …
definition of multiple myeloma to include validated biomarkers in addition to existing …
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International …
Summary The International Myeloma Working Group consensus aimed to provide
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Most patients with newly diagnosed multiple myeloma (MM) are aged> 65 years with 30%
aged> 75 years. Many elderly patients are also vulnerable because of comorbidities that …
aged> 75 years. Many elderly patients are also vulnerable because of comorbidities that …
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial
P Sonneveld, IGH Schmidt-Wolf… - Journal of clinical …, 2012 - repub.eur.nl
Purpose: We investigated whether bortezomib during induction and maintenance improves
survival in newly diagnosed multiple myeloma (MM). Patients and Methods: In all, 827 …
survival in newly diagnosed multiple myeloma (MM). Patients and Methods: In all, 827 …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Moreau, J San Miguel, P Sonneveld… - Annals of …, 2017 - annalsofoncology.org
Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from
3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive …
3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive …
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open …
Background In a phase 1b study, intravenous daratumumab plus pomalidomide and
dexamethasone induced a very good partial response or better rate of 42% and was well …
dexamethasone induced a very good partial response or better rate of 42% and was well …
[HTML][HTML] Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …
The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
A Van Rhenen, GAMS Van Dongen… - Blood, The Journal …, 2007 - ashpublications.org
In CD34+ acute myeloid leukemia (AML), the malignant stem cells reside in the CD38−
compartment. We have shown before that the frequency of such CD34+ CD38− cells at …
compartment. We have shown before that the frequency of such CD34+ CD38− cells at …